Kimby E, Mellstedt H, Nilsson B, Björkholm M, Holm G, Lindemalm C, Tribukait B
Department of Medicine, Danderyd Hospital, Sweden.
Hematol Oncol. 1988 Jan-Mar;6(1):47-55. doi: 10.1002/hon.2900060108.
The prognostic information of blood lymphocyte characteristics and clinical findings was assessed in 62 patients with chronic lymphocytic leukemia of B cell type. Bivariate and multivariate survival analyses were performed using age, Rai stage, surface membrane immunoglobulin (smIg) isotype pattern of the leukemic clone, total lymphocyte counts, numbers of proliferating lymphocytes and T cell subpopulations. Rai stages III and IV, high numbers of blood lymphocytes in S-phase (S+) and sm mu isotype were found to be partly independent factors predicting short therapy-free survival. Patients with a sm mu+ leukemic cell clone had a shorter therapy-free and total survival compared to those with sm mu+/delta+ and sm delta+ leukemic cells. Moreover, patients with high numbers of blood S+ lymphocytes had a shorter therapy-free and total survival compared to those with few S+ cells. These prognostic variables were valid also in patients with a low tumour burden (Rai stages 0, I and II) and may thus be of clinical importance as a guideline for therapeutic intervention.
对62例B细胞型慢性淋巴细胞白血病患者的血液淋巴细胞特征和临床检查结果的预后信息进行了评估。使用年龄、Rai分期、白血病克隆的表面膜免疫球蛋白（smIg）同种型模式、总淋巴细胞计数、增殖淋巴细胞数量和T细胞亚群进行双变量和多变量生存分析。发现Rai III期和IV期、S期血液淋巴细胞数量高（S+）和sm μ同种型是预测短无治疗生存期的部分独立因素。与具有sm μ+/δ+和sm δ+白血病细胞的患者相比，具有sm μ+白血病细胞克隆的患者无治疗生存期和总生存期更短。此外，与S+细胞数量少的患者相比，血液S+淋巴细胞数量高的患者无治疗生存期和总生存期更短。这些预后变量在肿瘤负荷低的患者（Rai 0期、I期和II期）中也有效，因此作为治疗干预的指导可能具有临床重要性。
